Comparing early and late ECMO treatment for severe respiratory failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial is a prospective randomized multicenter trial that investigates the timing of Extracorporal Membrane Oxygenation (ECMO) treatment in patients with Acute Respiratory Distress Syndrome (ARDS). Patients will be assigned to receive ECMO immediately upon admission to the intensive care unit or to undergo conservative treatment initially, with ECMO as a rescue option if conservative therapy fails. The study aims to enroll patients within 24 hours of ARDS symptom onset and will follow them for 90 days to assess outcomes such as mortality and organ failure scores.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ARDS as defined according to the Berlin Definition1
* The term "acute onset" is defined as follow: the duration of the hypoxemia criterion and the chest radiograph criterion must be ≤ 7 days at the time of randomization.
* Patients must be enrolled within 96 hours of onset of ARDS and no later than 7 days from the initiation of mechanical ventilation.

Exclusion Criteria:

* Age less than 18 years
* More than 7 days since initiation of mechanical ventilation
* more than 96 hours since meeting inclusion criteria
* patient, surrogate or physician not committed to full intensive care support
* pregnancy

Where it's running

• University hospital Tübingen
  Tübingen, Germany Recruiting

Study contacts

• Principal investigator: Peter Rosenberger, Prof. — University Hospital Tuebingen
• Study coordinator: Peter Rosenberger, Prof.
• Email: peter.rosenberger@med.uni-tuebingen.de
• Phone: +49707129

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Full-Course ECMO Pathway for Moderate-to-Severe ARDS

  This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.

  Recruiting at 15 sites Southeast University, China · Beijing and 38 other locations · NCT07726953

• Height measurement methods to guide ventilator settings in ARDS

  We’re testing whether more precise height measurements change how researchers set lung-protective tidal volumes in adults with ARDS who are on a ventilator.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07595926

• Corticosteroids for a hyperinflammatory state in critical illness

  This trial tests whether methylprednisolone helps improve organ function and survival in adults with sepsis or ARDS who show a hyperinflammatory profile.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07511582

• Right‑heart function and heart–lung interaction during ARDS with mechanical ventilation

  This project will follow adults with ARDS on mechanical ventilation to see how positive‑pressure breathing affects the right heart over time and how that relates to circulation.

  Recruiting Bicetre Hospital · Le Kremlin-Bicêtre · NCT07450846

• Umbilical‑cord mesenchymal stem cell and secretome therapy for severe ARDS

  This trial tests whether IV umbilical‑cord mesenchymal stem cells, alone or with secretome, help adults with severe ARDS recover lung function and reduce inflammation.

  Recruiting Phase 1/2 PT. Prodia Stem Cell Indonesia · Jakarta Pusat, DKI Jakarta · NCT07439848

• Human umbilical cord mesenchymal stem cell injection for moderate to severe ARDS

  This will test whether a single injection of human umbilical cord mesenchymal stem cells can help adults with moderate to severe ARDS that hasn't improved after standard treatment.

  Recruiting Phase 1/2 Changchun Tuohua Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07413978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.